Organization
Investigational Cancer Therapeutics Clinical Unit and Section of Oncology
4 abstracts
Abstract
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.Org: Memorial Sloan Kettering Cancer Center, Azienda Ospedaliera Universitaria Integrata di Verona, Hospital Universitario Miguel Servet, Centre Léon Bérard, Masaryk Memorial Cancer Institute,
Abstract
Precision medicine applied to rare malignancies: A single-center experience at University Hospital of Verona.Org: Medical Oncology Group, Azienda Ospedaliera Universitaria Integrata di Verona, Investigational Cancer Therapeutics Clinical Unit and Section of Oncology, ARC-Net Research Centre - Diagnostic and Public Health Department, University of Verona - Faculty of Medicine,
Abstract
Temporal trends of atypical drug access at an academic oncology unit: The Verona University Hospital experience.Org: Medical Oncology Group, Azienda Ospedaliera Universitaria Integrata di Verona, Pharmacy Service, Scuola di Specializzazione in Oncologia Medica, Investigational Cancer Therapeutics Clinical Unit and Section of Oncology,
Abstract
From seed to harvest: 18-month experience of molecular tumor board (MTB)-based precision oncology practice at the Verona University Hospital.Org: Medical Oncology Group, Azienda Ospedaliera Universitaria Integrata di Verona, ARC-Net Research Centre - Diagnostic and Public Health Department, University of Verona - Faculty of Medicine, Department of Diagnostics and Public Health,